{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:56:38Z","timestamp":1793422598851,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>Pancreatic islet autoantibodies (iAb) are the hallmark of autoimmunity in type 1 diabetes. A more comprehensive understanding of the global iAb prevalence could help reduce avertible morbidity and mortality among children and adolescents and contribute to the understanding in the observed differences in the incidence, prevalence and health outcomes of children and adolescents with type 1 diabetes across and within countries. We present the first scoping review that provides a global synthesis of the prevalence of iAb in children and adolescents with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research Design and Methods<\/jats:title>\n                    <jats:p>\n                      We searched Ovid MEDLINE\n                      <jats:sup>\u00ae<\/jats:sup>\n                      with Daily Update, Embase (Elsevier, embase.com) and PubMed (National Library of Medicine -NCBI), for studies pertaining to prevalence in children and adolescents (0-19) with type 1 diabetes published between 1 Jan 1990 and 18 June 2021. Results were synthesized using Covidence systematic review software and meta-analysis was completed using R v3\u00b76\u00b71. Two reviewers independently screened abstracts with a third reviewer resolving conflicts (k= 0\u00b792).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review revealed 125 studies from 48 different countries, with 92 from high-income countries. Globally, in new-onset type 1 diabetes, IA-2A was the most prevalent iAb 0\u00b7714 [95% CI (0\u00b771, 0\u00b772)], followed by ICA 0\u00b7681 [95% CI (0\u00b767, 0\u00b769)], ZnT8A was 0\u00b7654 [95% CI (0\u00b764, 0\u00b766)], GADA 0\u00b7636 [95% CI (0\u00b763, 0\u00b766)] and then IAA 0\u00b7424 [95% CI (0\u00b742, 0\u00b743)], with substantial variation across world regions. The weighted mean prevalence of IA-2A was more variable, highest in Europe at 0\u00b7749 [95% CI (0\u00b774, 0\u00b776)] followed by Northern America 0\u00b7662 [95% CI (0\u00b764, 0\u00b769)], Latin America and the Caribbean 0\u00b7632 [95% CI (0\u00b754, 0\u00b772)], Oceania 0\u00b7603 [95% CI (0\u00b754, 0\u00b767)], Asia 0\u00b7466 [95% CI (0\u00b744, 0\u00b750)] and Africa 0\u00b7311 [95% CI (0\u00b723, 0\u00b740)]. In established cases of type 1 diabetes, GADA was the most prevalent iAb 0\u00b7407 [95% CI (0\u00b739, 0\u00b742)] followed by ZnT8A 0\u00b7322 [95% CI (0\u00b729, 0\u00b736)], IA-2A 0\u00b7302 [95% CI (0\u00b729, 0\u00b732)], IAA 0\u00b7258 [95% CI (0\u00b724, 0\u00b726)] and ICA 0\u00b7145 [95% CI (0\u00b713, 0\u00b716)], again with substantial variation across world regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Understanding the global prevalence of iAb in children and adolescents with type 1 diabetes could help with earlier identification of those at-risk of developing type 1 diabetes and inform clinical practice, health policies, resource allocation, and targeted healthcare interventions to better screen, diagnose and manage children and adolescents with type 1 diabetes<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2022.815703","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:52:47Z","timestamp":1643860367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["The Prevalence of Islet Autoantibodies in Children and Adolescents With Type 1 Diabetes Mellitus: A Global Scoping Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Carlo","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Gomber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira","family":"Owais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ch\u00e9-L.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat","family":"Atun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 Diabetes Mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2004.08.002","article-title":"SEARCH for Diabetes in Youth: A Multicenter Study of the Prevalence, Incidence and Classification of Diabetes Mellitus in Youth","volume":"25","year":"2004","journal-title":"Control Clin Trials"},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 Diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.05.011","article-title":"Epidemiology of Type 1 Diabetes","volume":"39","author":"Maahs","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","first-page":"107842","DOI":"10.1016\/j.diabres.2019.107842","article-title":"Worldwide Estimates of Incidence, Prevalence and Mortality of Type 1 Diabetes in Children and Adolescents: Results From the International Diabetes Federation Diabetes Atlas, 9th Edition","volume":"157","author":"Patterson","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.34172\/hpp.2020.18","article-title":"Prevalence and Incidence of Type 1 Diabetes in the World: A Systematic Review and Meta-Analysis","volume":"10","author":"Mobasseri","year":"2020","journal-title":"Heal Promot Perspect"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-102090","article-title":"Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates With Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression","volume":"50","author":"Gro\u00dfe","year":"2018","journal-title":"Horm Metab Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2690-2","article-title":"Variation Between Countries in the Frequency of Diabetic Ketoacidosis at First Presentation of Type 1 Diabetes in Children: A Systematic Review","volume":"55","author":"Usher-Smith","year":"2012","journal-title":"Diabetol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32833a46a7","article-title":"Adherence Challenges in the Management of Type 1 Diabetes in Adolescents: Prevention and Intervention","volume":"22","author":"Borus","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-444-56378-1.00046-0","article-title":"Glutamic Acid Decarboxylase Antibody","volume-title":"Autoantibodies","author":"Crotti","year":"2014"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90140-8","article-title":"Iislet-Cell Antibodies in Diabetes Mellitus with Autoimmune Polyendocrine Deficiencies","volume":"304","author":"Bottazzo","year":"1974","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jama.2019.21565","article-title":"Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany","volume":"323","author":"Ziegler","year":"2020","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/jc.2009-1365","article-title":"Clinical Applications of Diabetes Antibody Testing","volume":"95","author":"Bingley","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1419","article-title":"Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0023","article-title":"Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association","volume":"41","author":"Chiang","year":"2018","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/08916930701619169","article-title":"Autoantibodies in Type 1 Diabetes","volume":"41","author":"Taplin","year":"2008","journal-title":"Autoimmun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12734","article-title":"ISPAD Clinical Practice Consensus Guidelines 2018: Stages of Type 1 Diabetes in Children and Adolescents","volume":"19","author":"Couper","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400364","article-title":"A Nationwide Population-Based Study of the Familial Aggregation of Type 1 (Insulin-Dependent) Diabetes Mellitus in Denmark. Danish Study Group of Diabetes in Childhood","volume":"36","author":"Pociot","year":"1993","journal-title":"Diabetol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3457","article-title":"Emerging Effects of Early Environmental Factors Over Genetic Background for Type 1 Diabetes Susceptibility: Evidence From a Nationwide Italian Twin Study","volume":"97","author":"Nistic\u00f2","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198407193110304","article-title":"Differences in Risk of Insulin-Dependent Diabetes in Offspring of Diabetic Mothers and Diabetic Fathers","volume":"311","author":"Warram","year":"1984","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/pedi.13066","article-title":"High Prevalence of Idiopathic (Islet Antibody-Negative) Type 1 Diabetes Among Indian Children and Adolescents","volume":"22","author":"Vipin","year":"2021","journal-title":"Pediatr Diabetes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/jc.2006-1494","article-title":"Prevalence of Autoantibody-Negative Diabetes is Not Rare at All Ages and Increases With Older Age and Obesity","volume":"92","author":"Wang","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1026","article-title":"Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-Up","volume":"34","author":"Elding Larsson","year":"2011","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13410-018-0622-5","article-title":"Autoantibodies and HLA Class II DR-DQ Genotypes in Ugandan Children and Adolescents With Type 1 Diabetes Mellitus","volume":"39","author":"Bahendeka","year":"2019","journal-title":"Int J Diabetes Dev Ctries"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.12.2049","article-title":"Progression to Diabetes in Relatives With Islet Autoantibodies. Is it Inevitable","volume":"22","author":"Gardner","year":"1999","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.5.1346","article-title":"Genetic Effects on Age-Dependent Onset and Islet Cell Autoantibody Markers in Type 1 Diabetes","volume":"51","author":"Graham","year":"2002","journal-title":"Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.suppl_2.S52","article-title":"Autoantibodies in Diabetes","author":"Pihoker","year":"2005","journal-title":"Diabetes"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.11.1701","article-title":"Prediction of IDDM in the General Population: Strategies Based on Combinations of Autoantibody Markers","volume":"46","author":"Bingley","year":"1997","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.9.1403","article-title":"Evaluation of ICA512As in Combination With Other Islet Cell Autoantibodies at the Onset of IDDM","volume":"20","author":"Feeney","year":"1997","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1494","article-title":"Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for Repeat Screening Throughout Childhood","volume":"34","author":"Vehik","year":"2011","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2088","article-title":"Age of Islet Autoantibody Appearance and Mean Levels of Insulin, But Not GAD or IA-2 Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes: Diabetes Autoimmunity Study in the Young","volume":"34","author":"Steck","year":"2011","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.2337\/dc15-S005","article-title":"Classification and Diagnosis of Diabetes","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"B36","article-title":"Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management","year":"2020","journal-title":"NICE Guidel"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002","article-title":"Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20142021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e011144","DOI":"10.1136\/bmjopen-2016-011144","article-title":"Capillary Blood Islet Autoantibody Screening for Identifying Pre-Type 1 Diabetes in the General Population: Design and Initial Results of the Fr1da Study","volume":"6","author":"Raab","year":"2016","journal-title":"BMJ Open"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05229-x","article-title":"Type 1 Diabetes in Africa: An Immunogenetic Study in the Amhara of North-West Ethiopia","volume":"63","author":"Balcha","year":"2020","journal-title":"Diabetol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(92)90078-6","article-title":"Islet-Cell Antibodies and Endogenous Insulin Secretion in Sudanese Diabetic Children","volume":"16","author":"Elamin","year":"1992","journal-title":"Diabetes Res Clin Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12369","article-title":"Predominance of DR3 in Somali Children With Type 1 Diabetes in the Twin Cities, Minnesota","volume":"18","author":"Sunni","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"B42","article-title":"Population Division. Population Dynamics","year":"2019","journal-title":"World Popul Prospects"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.5.1534","article-title":"Diabetes-Associated Autoantibodies in Relation to Clinical Characteristics and Natural Course in Children With Newly Diagnosed Type 1 Diabetes. The Childhood Diabetes In Finland Study Group","volume":"84","author":"Sabbah","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1915-5","article-title":"Diabetes Antibody Standardization Program: Evaluation of Assays for Insulin Autoantibodies","volume":"53","author":"Schlosser","year":"2010","journal-title":"Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.815703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:52:50Z","timestamp":1643860370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.815703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":44,"alternative-id":["10.3389\/fendo.2022.815703"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.815703","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"article-number":"815703"}}